Non-small-cell lung cancer (NSCLC) accounts for approximately 70-80% of all lung cancers 2 and oncogenic activation of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), is especially relevant for this disease 3. This evidence concerns the gene EGFR and non-small cell lung carcinoma.